Butyrylcholinesterase deficiency is a genetic condition that affects how the body breaks down certain medicines used for anesthesia. People with Butyrylcholinesterase deficiency usually feel well day to day, but they can have very slow recovery from drugs like succinylcholine and mivacurium, with prolonged muscle weakness and trouble breathing after surgery. This condition is lifelong and often first noticed in adolescence or adulthood during a procedure, and not everyone will have the same experience. It is not linked to higher mortality when recognized, but unplanned exposure can be risky without proper monitoring and breathing support. Treatment focuses on avoiding trigger medicines, using alternatives, and providing ventilatory support until the drugs wear off, and genetic testing can sometimes clarify why Butyrylcholinesterase deficiency appears in families.
Overview
Butyrylcholinesterase deficiencySymptoms
Butyrylcholinesterase deficiency usually causes no day-to-day symptoms. Early signs of Butyrylcholinesterase deficiency appear after certain anesthesia medicines: unexpectedly prolonged muscle paralysis, slow breathing, and delayed waking, often needing temporary ventilation. This often follows drugs like succinylcholine.
Outlook and prognosis
Most people with butyrylcholinesterase deficiency live healthy lives between medical procedures. The main risk is prolonged muscle relaxation after certain anesthesia drugs; with planning, teams can prevent complications and support safe recovery. Family members may consider testing.
Causes and risk factors
Butyrylcholinesterase deficiency usually results from inherited BCHE gene changes (often autosomal recessive); a family history increases risk. Acquired reductions occur with liver disease, malnutrition, pregnancy, severe illness, or certain chemicals/medications (e.g., organophosphates, echothiophate). Risk varies by ancestry and consanguinity.
Genetic influences
Genetics play a central role in Butyrylcholinesterase deficiency; most cases are inherited due to variations in the BCHE gene. These changes reduce enzyme activity, slowing breakdown of certain anesthetics. Family history increases risk, so relatives may consider testing before surgery.
Diagnosis
Doctors suspect Butyrylcholinesterase deficiency after prolonged paralysis or breathing trouble following certain anesthesia medicines. Diagnosis is confirmed with blood enzyme activity testing (including the dibucaine number) and, when needed, genetic tests. Genetic diagnosis of Butyrylcholinesterase deficiency helps guide family screening.
Treatment and drugs
Treatment for Butyrylcholinesterase deficiency focuses on safe anesthesia planning and supportive care during procedures. Doctors choose non–succinylcholine muscle relaxants, monitor breathing closely, and provide ventilation until muscles recover. Genetic testing and a medical alert card help guide future care.
Symptoms
For most people living with butyrylcholinesterase deficiency, day-to-day life feels completely typical. The condition usually becomes clear only during or after anesthesia when certain muscle-relaxing medicines last far longer than expected. Early features of butyrylcholinesterase deficiency often appear the first time those drugs are used, such as a much longer recovery and needing help with breathing. Clinicians call this prolonged apnea, which means slow or paused breathing after these medicines.
After certain anesthesia muscle relaxants, arms and legs can feel limp and hard to move. The effect can last hours instead of minutes. Doctors may keep you supported until strength returns.
Breathing may become very slow or pause after drugs like succinylcholine or mivacurium. You may need a ventilator or manual support until the medicine wears off. This pattern is common in butyrylcholinesterase deficiency.
Getting out of the recovery phase takes longer than expected. Staff may wait to remove the breathing tube and keep you in the recovery area longer. Records often show an unusually long effect from the muscle relaxant.
Numbness from some older local anesthetics used for dental work or minor procedures may last longer than usual. Tingling or heaviness around the area can linger after others would have worn off. Mention this history before any future procedures.
How people usually first notice Butyrylcholinesterase deficiency?
Many people first notice butyrylcholinesterase deficiency when a routine surgery or procedure uses certain muscle relaxants, and waking up takes far longer than expected with prolonged muscle weakness or trouble breathing without support. Sometimes a family member’s similar reaction to anesthesia prompts testing, or a newborn screening or blood test done for another reason shows unusually low enzyme activity. If you’ve ever needed ventilation longer than usual after anesthesia or had relatives with the same issue, those experiences are common first signs of butyrylcholinesterase deficiency.
Types of Butyrylcholinesterase deficiency
Butyrylcholinesterase deficiency has a few well-recognized variants that differ in how strongly they slow the enzyme. These variants can change how long anesthesia medicines like succinylcholine or mivacurium last, ranging from a mild delay to hours of muscle paralysis that requires a breathing machine. People may also react differently to certain local anesthetics. Not everyone will experience every type.
Atypical (A) variant
This common variant makes the enzyme less responsive to a standard lab test blocker, and often causes a noticeable but limited prolongation of succinylcholine effects. Many people only discover it after an unexpected delay waking or moving after anesthesia. Early symptoms of butyrylcholinesterase deficiency often appear during a first surgery.
Fluoride-resistant (F)
This variant resists inhibition by fluoride in lab testing and can further reduce enzyme activity when combined with other variants. On its own, it may cause mild to moderate prolongation of certain muscle relaxants. Severity often depends on whether one or both gene copies carry a change.
Silent (S) variants
These rare changes lead to very low or nearly absent enzyme activity. People with two silent variants can have marked, hours-long paralysis after standard doses of succinylcholine or mivacurium. Care teams usually avoid these drugs once the variant is known.
Kalow (K) variant
This variant lowers enzyme levels or efficiency, which can moderately extend the action of triggering anesthetics. Effects can be stronger when combined with another non-working variant. Family members sometimes share similar results on the dibucaine number test.
Heterozygous carriers
People with a single changed gene often have partially reduced activity and a slight to moderate reaction to specific anesthetics. Some notice only a brief delay in recovery, while others have more pronounced effects. Testing can help estimate individual risk before procedures.
Homozygous deficiency
When both gene copies are affected, enzyme activity is very low and drug effects are most prolonged. This can require temporary ventilation support and careful choice of non-triggering medicines. Planning with anesthesia teams greatly reduces risk.
What genetics can tell you about symptoms
Some people with BCHE gene changes feel unusually long numbness or muscle weakness after certain anesthesia medicines, like succinylcholine. Specific variants slow the enzyme that clears these drugs, so effects linger—causing prolonged paralysis, breathing support needs, or delayed recovery.
Causes and risk factors
Butyrylcholinesterase deficiency most often stems from an inherited change in the BCHE gene that lowers the enzyme’s activity. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Family history and carrying two BCHE variants are key risk factors for Butyrylcholinesterase deficiency. Liver disease, severe infection, pregnancy, burns, cancer, and malnutrition can lower enzyme levels even without the gene change. Certain medicines, organophosphate insecticides, and heavy alcohol use can further reduce activity, so anesthesia muscle relaxants may last much longer.
Environmental and biological risk factors
Butyrylcholinesterase deficiency affects how your body breaks down certain medicines used in anesthesia and a few other compounds. You may not notice anything day to day, so early symptoms of Butyrylcholinesterase deficiency often show up only after a procedure—for example, longer-than-expected muscle weakness after a routine surgery. It helps to know what biological states and environmental exposures can lower this enzyme and increase the chance of a reaction. That said, biology and environment work hand in hand.
Because this enzyme is made in the liver, liver conditions can lower its level. People with cirrhosis or hepatitis have a higher chance of butyrylcholinesterase deficiency during anesthesia.
Natural shifts in late pregnancy and the first weeks after delivery reduce enzyme activity. This temporary dip can increase the chance of Butyrylcholinesterase deficiency when certain muscle relaxants are used.
Babies start life with lower enzyme activity that slowly rises over months. This can make butyrylcholinesterase deficiency more likely if anesthesia is needed in early infancy.
Major injuries can suppress enzyme production for a time. During this phase, butyrylcholinesterase deficiency is more likely to be unmasked by anesthesia medicines.
Genetic risk factors
Most cases of Butyrylcholinesterase deficiency stem from changes in a single gene called BCHE. The genetic causes of Butyrylcholinesterase deficiency usually follow an autosomal recessive pattern, where two altered copies lead to low enzyme levels and one altered copy often causes a milder, partial change. Carrying a genetic change doesn’t guarantee the condition will appear, but it does influence how much of this enzyme your body makes.
BCHE gene variants: Changes in the BCHE gene reduce or block the butyrylcholinesterase enzyme. Some variants cause a mild drop in activity, while others are silent variants that nearly eliminate it. The specific variant often predicts enzyme level.
Autosomal recessive pattern: The condition usually appears when two nonworking gene copies are inherited, one from each parent. Parents who carry a single variant typically have no symptoms and are considered carriers.
Carrier status: People with one altered BCHE gene often have partial deficiency but usually no day-to-day symptoms. When two carriers have a child, each pregnancy has a 1 in 4 (25%) chance of the child inheriting two altered copies. Carriers can be identified by genetic testing or enzyme activity testing.
Compound heterozygosity: Having two different BCHE variants, one on each gene copy, can also cause deficiency. The mix of variants shapes how low the enzyme level is.
Population patterns: Founder variants have made certain BCHE changes more common in specific ancestries. This means some families and communities have higher carrier rates. Exploring your family’s health background is a valuable starting point.
Family history: A parent, sibling, or child with Butyrylcholinesterase deficiency increases the chance you carry the same BCHE variant. Knowledge can help families feel more prepared and less anxious. Genetic counseling can clarify personal risk.
Related parents: When parents are closely related by blood, they are more likely to carry the same BCHE variant. This raises the chance that a child inherits two altered copies.
Variant severity: Different BCHE variants affect enzyme activity to different degrees. Severe or silent variants on both copies usually produce the lowest enzyme levels. People with the same risk factor can have very different experiences.
Lifestyle risk factors
Butyrylcholinesterase deficiency is typically inherited, and lifestyle habits do not cause it. However, daily choices can influence how the condition shows up during drug exposure—especially with certain anesthetics and recreational substances—and may modify complication risks. Below are lifestyle risk factors for Butyrylcholinesterase deficiency that can lower enzyme activity or magnify drug effects, illustrating how lifestyle affects Butyrylcholinesterase deficiency.
Inadequate protein can reduce liver production of butyrylcholinesterase, further lowering already limited enzyme activity. This may prolong the action of drugs broken down by this enzyme, such as succinylcholine and some ester local anesthetics.
Rapid weight loss or very low-calorie plans can impair hepatic enzyme synthesis. This can increase the risk of prolonged paralysis or longer sedation when enzyme-dependent drugs are used.
Chronic heavy drinking can injure the liver and diminish butyrylcholinesterase levels. Lower enzyme activity can intensify and extend the effects of succinylcholine, mivacurium, and certain ester anesthetics.
Cocaine is partly metabolized by butyrylcholinesterase, so deficiency increases cocaine toxicity and duration of effect. Using cocaine can therefore pose higher cardiovascular and neurologic risks in this condition.
Risk prevention
For most people, Butyrylcholinesterase deficiency only shows up during medical care—especially with certain anesthesia drugs—so prevention focuses on avoiding triggers and planning ahead. Talk to your doctor about which preventive steps are right for you. Share your history early before any procedure so the team can choose safer alternatives and monitor breathing closely. If problems happen, early symptoms of Butyrylcholinesterase deficiency usually appear after specific medicines, such as slow waking, weak breathing, or trouble moving.
Always mention Butyrylcholinesterase deficiency before surgeries, dental work, or emergency care. It helps the team avoid risky medicines and set up safer anesthesia plans.
A medical alert bracelet or phone tag can guide responders if you can’t speak. It helps them recognize early symptoms of Butyrylcholinesterase deficiency after certain drugs and act quickly.
If you or a family member had prolonged paralysis after anesthesia, ask about a blood test (like the dibucaine number) or genetic testing. Results can confirm risk and shape anesthesia choices.
Skip succinylcholine, mivacurium, and ester local anesthetics such as procaine or chloroprocaine. Safer options often include amide local anesthetics and nondepolarizing muscle relaxants.
Transmission
Butyrylcholinesterase deficiency is not contagious—you can’t catch it from someone else. In most cases, it runs in families in an autosomal recessive pattern: each parent typically carries one BCHE gene change without symptoms; with each pregnancy there’s a 25% chance the child will have the deficiency, a 50% chance the child will be a carrier, and a 25% chance the child will inherit neither change. New gene changes can happen for the first time in a child, but this is uncommon. Some people have a temporary or acquired drop in this enzyme due to pregnancy, severe liver disease, malnutrition, or certain medicines or pesticide exposures; that is not the genetic transmission of Butyrylcholinesterase deficiency and it is not passed to children.
When to test your genes
Consider genetic testing if you’ve had unexpectedly prolonged anesthesia recovery, severe reactions to succinylcholine or mivacurium, or a family history of similar events. Testing is also reasonable before planned surgery or if close relatives are known carriers. Results can guide anesthesia choices and alert family members who may benefit from testing.
Diagnosis
For many, the first clue comes after surgery—waking up much slower than expected or needing breathing support longer than others. Doctors usually begin by reviewing what happened during anesthesia and any family history of similar reactions, then confirm with specific lab tests. The diagnosis of Butyrylcholinesterase deficiency is based on a pattern of prolonged paralysis after certain drugs plus blood and, when needed, genetic tests. Getting clear answers helps tailor future anesthesia plans so procedures stay safe.
Providers ask about any prior prolonged paralysis or slow wake-up after surgery. They also look for reactions to specific muscle relaxants or certain local anesthetics. A family history of similar episodes is a helpful clue.
Teams review which medicines were used, especially succinylcholine or mivacurium. Unusually long paralysis compared with the dose and timing raises suspicion. Notes from recovery can show how long breathing support was needed.
A blood test measures butyrylcholinesterase activity in the plasma. Markedly low activity supports the diagnosis, but levels can drop temporarily with illness, pregnancy, or liver problems. Timing and repeat testing may be important.
This lab test shows how strongly the enzyme is inhibited by the drug dibucaine. A lower number points to an atypical enzyme variant linked with genetic Butyrylcholinesterase deficiency. It helps distinguish carriers from those more severely affected.
Stages of Butyrylcholinesterase deficiency
Butyrylcholinesterase deficiency does not have defined progression stages. It generally doesn’t change over time and usually only shows up when certain anesthesia medicines are used, so people typically do not have early symptoms of butyrylcholinesterase deficiency in day-to-day life. Diagnosis relies on your history—such as a past episode of slow waking or trouble breathing after medicines like succinylcholine or mivacurium—along with a blood test that measures this enzyme (and sometimes a related value called the dibucaine number) and, in some cases, genetic testing; pre-surgery testing may be suggested if you or a family member had this kind of reaction before. Many people feel reassured knowing what their tests can—and can’t—show.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially after finding out they have Butyrylcholinesterase deficiency. For most people, day-to-day life is unaffected between medical procedures. The main risk appears during or after anesthesia with certain medicines, like succinylcholine or mivacurium, which can lead to much longer-than-expected muscle paralysis and trouble breathing. When this condition is recognized in advance and those drugs are avoided, the long-term outlook is generally very good, and life expectancy is typically normal.
Prognosis refers to how a condition tends to change or stabilize over time. Butyrylcholinesterase deficiency doesn’t usually “progress” or cause ongoing organ damage; it’s a lifelong trait that mainly shows up in specific situations. People with the hereditary form often discover it after a family member has prolonged paralysis following surgery, or after their own first exposure. Early symptoms of Butyrylcholinesterase deficiency may only appear in that context—such as delayed waking, weak breathing, or needing a ventilator longer than expected—rather than everyday symptoms.
The future may look uncertain now, but with clear documentation in your medical record, a medical alert card or bracelet, and an anesthesia plan that avoids triggering medications, most people have safe surgeries and normal recovery. Serious complications and death are rare when the team is prepared, because supportive breathing and alternative drugs work well. Talk with your doctor about what your personal outlook might look like, including whether relatives should be tested, and what to do in emergencies. Knowing what to expect can ease some of the worry and helps ensure every care team is ready before procedures or dental sedation.
Long-term effects
Butyrylcholinesterase deficiency is a lifelong enzyme trait that usually causes no day-to-day symptoms. Problems mainly appear during or after anesthesia with certain muscle relaxants, when recovery can take much longer and breathing may stay weak. Long-term effects vary widely, and most people have no ongoing issues between procedures. Even so, the risk of delayed waking after surgery can persist across a lifetime.
In Butyrylcholinesterase deficiency, certain anesthetic muscle relaxants can last far longer than expected. Muscle weakness and paralysis may continue for hours after surgery.
Weak breathing can persist after the procedure. Some need short-term ventilatory support until the medicine wears off.
Strong reactions occur with succinylcholine or mivacurium, while other medicines act normally. The same pattern often repeats with every exposure.
Outside medical procedures, most people feel completely well. Many never notice early symptoms of Butyrylcholinesterase deficiency unless exposed to these drugs.
How is it to live with Butyrylcholinesterase deficiency?
Living with butyrylcholinesterase deficiency is usually uneventful day to day, because most people feel entirely normal and only learn about it after an unexpected, long-lasting paralysis or very slow wake-up following certain anesthetics or muscle relaxants during surgery. The main practical shift is planning: carrying medical alert information, telling every surgical, dental, or emergency team ahead of time, and ensuring safer medication choices are used to avoid prolonged effects. Family members may be affected too, since this condition is often inherited, so sharing the diagnosis can help relatives decide whether to get tested before they ever need anesthesia. With these precautions, most people go on with work, exercise, travel, and caregiving as usual, while those around them simply learn the few drugs to avoid and how to advocate in medical settings.
Treatment and drugs
Treatment for Butyrylcholinesterase deficiency focuses on preventing and safely managing long-lasting muscle relaxation after certain anesthesia drugs, especially succinylcholine and mivacurium. Before surgery or procedures, tell your care team about the condition so they can choose alternative medicines and plan for closer monitoring. If you do receive one of these drugs and wake-up is delayed, supportive care can make a real difference in how you feel day to day: doctors provide breathing support and sedation until the medicine naturally wears off, which usually resolves the issue without lasting harm. There’s no daily medication needed for most people with Butyrylcholinesterase deficiency, but wearing medical alert identification and having the diagnosis in your medical record helps avoid problems in emergencies. Your doctor may suggest testing close relatives, since knowing about the condition ahead of time helps guide safe anesthesia choices.
Non-drug treatment
Most people with Butyrylcholinesterase deficiency feel well day to day, but anesthesia and certain emergency medicines can last much longer than expected. Planning ahead helps keep procedures safe and recovery smoother. Non-drug treatments often lay the foundation for safer surgery and peace of mind. Early symptoms of Butyrylcholinesterase deficiency usually show up only after specific anesthesia drugs are used, such as unusually prolonged muscle weakness or trouble breathing on your own.
Tell your surgical and anesthesia team about the condition before any procedure, even minor ones. Share previous anesthesia records and carry a summary letter from your clinician.
Anesthesiologists can avoid trigger drugs like succinylcholine or mivacurium and use alternatives. Regional or local anesthesia may be possible for some procedures.
During surgery, teams can track muscle response with simple nerve-stimulation monitors. This helps fine-tune dosing and timing so recovery is safer for people with Butyrylcholinesterase deficiency.
If muscle relaxation lasts longer than expected, temporary ventilation and sedation keep you comfortable and safe. Care teams support breathing until your own muscles fully recover.
Your genes may have an impact on how drugs work for you
Medicines that affect nerve signaling, anesthesia, or certain pain relievers can act differently in people with butyrylcholinesterase deficiency because the enzyme that helps clear some drugs is reduced or slower. This can lead to stronger or longer effects, so dosing and drug choice are adjusted.
Pharmacological treatments
Medicines for Butyrylcholinesterase deficiency focus on preventing drug-related complications during anesthesia and speeding recovery if exposure happens. Early symptoms of Butyrylcholinesterase deficiency are often absent until certain medications are given, so planning ahead is key. Alternatives to specific muscle relaxants and careful choice of local anesthetics help avoid prolonged paralysis or numbness. In emergencies, supportive treatments can bridge the gap while the body clears the drug.
Rocuronium, vecuronium, atracurium, or cisatracurium are used instead of succinylcholine or mivacurium. These choices do not depend on butyrylcholinesterase and are safer for planned procedures. Not everyone responds to the same medication in the same way.
Sugammadex can rapidly reverse rocuronium or vecuronium paralysis. It works independently of butyrylcholinesterase, making it a reliable option in this condition. Dosing is based on body weight and the depth of muscle blockade.
Fresh frozen plasma (FFP) supplies butyrylcholinesterase and can shorten recovery after unintended succinylcholine or mivacurium exposure. It is given through a vein in the hospital while breathing is supported. The benefits must be weighed against transfusion risks.
Amide local anesthetics such as lidocaine, bupivacaine, and ropivacaine are preferred over ester types like procaine, chloroprocaine, and tetracaine. This reduces the chance of prolonged numbness or toxicity. Make sure dental and minor procedure teams are aware of the diagnosis.
Genetic influences
For most people, this condition traces back to changes in a single gene called BCHE, which lower the activity of the butyrylcholinesterase enzyme that helps clear certain muscle‑relaxing anesthesia medicines. Butyrylcholinesterase deficiency is usually inherited in an autosomal recessive pattern, meaning you typically need two changed copies—one from each parent—to be fully affected. A “carrier” means you hold the gene change but may not show symptoms. Carriers often feel well in daily life, while those with two gene changes can have a much longer‑than‑expected effect from these medicines during procedures. If both parents carry a BCHE change, each pregnancy has a 1 in 4 (25%) chance of a child having Butyrylcholinesterase deficiency. Severity of Butyrylcholinesterase deficiency can vary from person to person, even within the same family. Genetic testing for Butyrylcholinesterase deficiency, along with a simple blood enzyme test, can confirm the cause and help your care team plan safer anesthesia for you and your relatives.
Is Butyrylcholinesterase deficiency genetic?
Genetics play a central role in Butyrylcholinesterase deficiency; most cases are inherited due to variations in the BCHE gene. These changes reduce enzyme activity, slowing breakdown of certain anesthetics. Family history increases risk, so relatives may consider testing before surgery.
Pharmacogenetics—how genetics influence drug effects
In Butyrylcholinesterase deficiency, inherited changes in the enzyme that clears certain anesthesia drugs can significantly change how long those medicines stay active. A “slow metabolizer” may process medicine more slowly, causing longer-than-expected muscle relaxation and need for breathing support after drugs like succinylcholine or mivacurium. Because of this pharmacogenetic effect, care teams often avoid these drugs and instead use alternatives such as rocuronium (which can be reversed with sugammadex) or choose amide local anesthetics rather than ester types. Knowing about Butyrylcholinesterase deficiency before a procedure lets anesthesiologists plan doses and monitoring to reduce the chance of unexpectedly prolonged paralysis. Testing—such as a blood enzyme study (for example, a dibucaine number) or preoperative pharmacogenetic testing for Butyrylcholinesterase deficiency—can confirm the risk and guide care for relatives who might carry the same change. Temporary drops in this enzyme can also occur with illness, pregnancy, or certain medicines, but the inherited form typically has the biggest impact on anesthesia choices and timing.
Interactions with other conditions
Butyrylcholinesterase deficiency mostly shows up when certain medicines are used, so interactions often center on surgery, anesthesia, and a few specific drugs. Conditions that lower enzyme activity—such as advanced liver disease, severe malnutrition, pregnancy, major burns, or some cancers—can intensify the effect, making muscle relaxants like succinylcholine or mivacurium last much longer than expected. Breathing problems can be more likely if someone also lives with asthma, COPD, sleep apnea, or a neuromuscular disorder, because prolonged muscle relaxation can compound existing respiratory weakness. Exposure to organophosphate pesticides or nerve agents can temporarily block the enzyme and worsen Butyrylcholinesterase deficiency, and cocaine or older “ester” local anesthetics may linger longer and raise toxicity risks, especially in people with heart or brain conditions. Many people have no early symptoms of Butyrylcholinesterase deficiency, so these interactions often come to light only during procedures or after certain exposures. Talk with your doctor about how your conditions may influence each other.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of people who stayed sleepy or weak far longer than expected after surgery. A relative would wake up hours late after a routine procedure, or need help breathing in the recovery room, while others stirred within minutes. Before modern testing, these delayed recoveries puzzled both patients and clinicians.
Throughout history, people have described unusual reactions to plant- or medicine-based sedatives and muscle relaxants. The pattern became clearer in the mid-20th century when certain anesthesia drugs, especially those used to relax muscles for intubation, led some people to remain paralyzed long after the operation. Doctors tracked these prolonged effects and realized the issue wasn’t the surgery itself, but how the body cleared specific drugs.
First described in the medical literature as an abnormally slow breakdown of muscle relaxants, this was later connected to a missing or reduced activity of an enzyme in the blood, now known as butyrylcholinesterase. In the 1950s and 1960s, careful bedside observations, family histories, and simple blood tests showed that some families had a consistent, inherited tendency toward prolonged paralysis after anesthesia. From these first observations, researchers identified genetic differences that reduce the enzyme’s activity.
As medical science evolved, the story of Butyrylcholinesterase deficiency shifted from unexplained anesthesia delays to a recognized, mostly silent trait that shows up only when certain drugs are used. Early reports noted dramatic episodes in operating rooms. Later studies filled in the quieter side: most people with Butyrylcholinesterase deficiency feel completely well in daily life and discover it only after a prolonged recovery or through preoperative screening.
Advances in genetics confirmed that changes in the BChE gene can be passed down in families, with enzyme activity acting like a dimmer switch—fully bright in some, turned down in others. Over time, descriptions became more precise, distinguishing between mild reductions that cause slight delays and more marked deficiency linked to hours of extended drug effect. Not every early description was complete, yet together they built the foundation of today’s knowledge.
With modern anesthesia practice, awareness and testing have reduced risks. Simple blood enzyme measurements and, in some centers, genetic testing help identify people at risk before surgery. Many living with Butyrylcholinesterase deficiency now carry medical alerts or note it on health forms, so teams can choose alternative medications. Looking back helps explain why a grandparent’s “long nap” after surgery now leads to a straightforward plan: avoid certain drugs, monitor closely, and recover on time.